Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2001
03/20/2001US6203991 Inhibition of smooth muscle cell migration by heme oxygenase I
03/20/2001US6203979 Polynucleotide which codes for protein of defined amino acid sequences; diagnosis, prevention, and therapy of cell proliferative and immune disorders; anticarcinogenic agents; antiproliferative/antiarthritic agents; crohn's disease
03/20/2001US6203976 Drug screening using eukaryotic cells with dna construct of regulatory sequence and promoter linked to reporter gene, contacting with chemical, quantitatively determining signal produced, comparing to controls, then mixing with carrier
03/20/2001US6203820 Comprising molybdenum and at least two amino acids selected from l-arginine, l-cystine, l-histidine, l-isoleucine, l-leucine, l-lysine, l-methionine, l-phenylalanine, l-threonine, l-tryptophan, l-tyrosine, and l-valine
03/20/2001US6203805 Topical compositions containing whey proteins
03/20/2001US6203800 Screening for antibacterial agents; genetic engineering
03/20/2001US6203797 Freeze dried aloe, vitamin b6 hydrochloride, manganes, glutamine, fructooligosaccharides and dahlia inulin juice
03/20/2001US6203795 Polypeptide; antibody h23 recognizes tumor antigen expressed on breast cancer cells
03/20/2001US6203794 Botulinum or tetanus toxin conjugated to drug; treating neurvous system and muscular disorders
03/20/2001US6203793 Compositions and methods for treating thermal injury
03/20/2001US6203792 Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
03/20/2001US6203790 Genetic engineering; antiinflammatory agents
03/20/2001US6203789 Treating erythrocytes with s-nitroso-cysteine, homocysteine, or cysteinylglycine to reduce blood pressure
03/20/2001US6203788 Implanting cellular adhesion molecule and schwann or oligodendrocyte progenitor cell(s); inhibiting n-cadherin-mediated cell adhesion; treating muliple sclerosis
03/20/2001US6203787 Treating tumors using implants comprising combinations of allogeneic cells
03/20/2001CA2102429C Bone growth factors and inhibitors of bone resorption for promoting bone formation
03/20/2001CA2098303C Synthetic bioadhesive polypeptide
03/20/2001CA2070169C Compounds with a sequence of three radicals, the central one being -aminoacidic and therapeutical applications thereof
03/20/2001CA1341207C Analogues of insulin-like growth factor-1
03/20/2001CA1341206C Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
03/15/2001WO2001018550A2 Determination of adrenomedullin-binding proteins
03/15/2001WO2001018546A2 Screening for inhibitors of 'paired helical filaments'
03/15/2001WO2001018541A1 Use of beta2gpi in diagnostic tests for autoimmune diseases
03/15/2001WO2001018236A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
03/15/2001WO2001018227A1 Novel compound f-15078
03/15/2001WO2001018224A1 Adenoviral vectors modified for increased and persistent expression of the cystic fibrosis transmembrane conductance regulator gene in human airway epithelia
03/15/2001WO2001018216A2 26176, a novel calpain protease and uses thereof
03/15/2001WO2001018215A1 Method for producing active serine proteases and inactive variants
03/15/2001WO2001018212A2 Mycobacterium paratuberculosis-specific antigens and their diagnostic uses
03/15/2001WO2001018210A1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
03/15/2001WO2001018209A1 Fibroblast growth factor polypeptide and nucleic acids encoding same
03/15/2001WO2001018208A2 Interferon induced polynucleotides and proteins encoded thereby
03/15/2001WO2001018207A1 Human 7tm proteins receptors and polynucleotides encoding the same
03/15/2001WO2001018206A1 Human g-protein coupled 7 transmembrane receptor and polynucleotides encoding the same
03/15/2001WO2001018204A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby
03/15/2001WO2001018203A1 Opg fusion protein compositions and methods
03/15/2001WO2001018202A2 Flint analog compounds and formulations thereof
03/15/2001WO2001018200A1 Tsg-like gene
03/15/2001WO2001018184A1 Variant nucleoside-5'-phosphate producing enzyme
03/15/2001WO2001018178A1 Nucleic acids and polypeptides of invertebrate bioamine transporter and methods of use
03/15/2001WO2001018176A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
03/15/2001WO2001018172A2 Fibroblast growth factor-like polypeptides
03/15/2001WO2001018169A2 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
03/15/2001WO2001018055A1 Flint analog compounds and formulations thereof
03/15/2001WO2001018053A1 Method for detecting and purifying tcd8+ lymphocyte populations, specific of peptides present in the context of hla
03/15/2001WO2001018052A1 Monomeric analogues of human insulin
03/15/2001WO2001018051A2 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
03/15/2001WO2001018049A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies
03/15/2001WO2001018046A2 Ovarian tumor sequences and methods of use therefor
03/15/2001WO2001018044A2 Use of semaphorin for modulation of cellular efflux
03/15/2001WO2001018043A2 Neurogenic compositions and methods
03/15/2001WO2001018042A2 Apoptosis proteins
03/15/2001WO2001018041A2 Flint proteins and formulations thereof
03/15/2001WO2001018040A2 Use of leptin in inhibition of endothelial cell proliferation
03/15/2001WO2001018039A2 INCREASED PRODUCTION OF INTERFERON-$g(a)
03/15/2001WO2001018038A2 Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
03/15/2001WO2001018037A2 A p53-induced protein with a death domain that can promote apoptosis
03/15/2001WO2001018036A2 Methods and reagents for regulating gene expression
03/15/2001WO2001018035A2 Muc-1 derived peptides
03/15/2001WO2001018033A1 Gamma-carboxyglutamate containing conopeptides
03/15/2001WO2001018030A2 Small peptides having potent anti-angiogenic activity
03/15/2001WO2001018024A1 Antisense modulation of x-linked inhibitor of apoptosis expression
03/15/2001WO2001018023A1 Antisense modulation of pi3 kinase p110 beta expression
03/15/2001WO2001018022A1 52 human secreted proteins
03/15/2001WO2001018021A1 B7-like polynucleotides, polypeptides, and antibodies
03/15/2001WO2001018019A1 Epithelial protein lost in neoplasm (eplin)
03/15/2001WO2001018018A1 Murf gene and enzyme ofpseudomonas aeruginosa
03/15/2001WO2001017995A1 Tyrosine kinase inhibitors
03/15/2001WO2001017985A1 Novel derivatives of flavones, xanthones and coumarins
03/15/2001WO2001017614A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
03/15/2001WO2001017568A2 Bioconjugation in vivo to pulmonary or blood components
03/15/2001WO2001017563A2 Integrin-mediated drug targeting
03/15/2001WO2001017559A1 Semaphorin modulation of immune cell migration
03/15/2001WO2001017558A2 Novel uses of mammalian ccr6 receptors and related reagents
03/15/2001WO2001017557A1 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
03/15/2001WO2001017552A1 Kaposi's sarcoma-associated herpesvirus ks-sm gene product and uses thereof
03/15/2001WO2001017548A2 Use of natriuretic peptides as antibiotically effective substances for treating bacterial infections
03/15/2001WO2001017547A2 Bmp-9 compositions and methods for inducing differentiation of cholinergic neurons
03/15/2001WO2001017546A1 Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
03/15/2001WO2001017545A1 Remedies for nervous diseases
03/15/2001WO2001017544A1 Peptides that bind to urokinase receptor
03/15/2001WO2001017543A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
03/15/2001WO2001017541A1 Composition for extending post meal satiety
03/15/2001WO2001017538A1 Use of oyster flesh enzymatic hydrolysates for preparing compositions eliminating free radicals
03/15/2001WO2001017536A2 Novel autogenous vaccines used to obtain an immune tolerance
03/15/2001WO2001017532A1 Human neuropeptide receptor
03/15/2001WO2001017524A1 Methods for treating cell proliferative disorders including cancer
03/15/2001WO2001017522A1 Method of treating cancer using tetraethyl thiuram disulfide
03/15/2001WO2001017506A1 Proteinic drug delivery system using membrane mimetics
03/15/2001WO2001017480A2 Methods and compositions for preventing and treating urinary tract disorders
03/15/2001WO2001017479A2 Methods and compositions for preventing and treating prostate disorders
03/15/2001WO2001017369A1 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'
03/15/2001WO2001002429A3 Angiopoietin-6 and uses thereof
03/15/2001WO2000077198A3 Identification and molecular characterisation of proteins, expressed in the tick salivary glands
03/15/2001WO2000071152A9 Fibroblast growth factor 10
03/15/2001WO2000069425A3 Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
03/15/2001WO2000066732A3 Laminin 8 and methods for its use
03/15/2001WO2000066178A9 Lim mineralization protein splice variants
03/15/2001WO2000064468A3 Therapeutic compositions and methods for enhancing angiogenesis
03/15/2001WO2000061610A3 Prostate-restricted gene 30p3c8 expressed in prostate cancer